Jardiance Dosage/Direction for Use

Testing Prior to Initiation of JARDIANCE: Assess renal function before initiating JARDIANCE and as clinically indicated (see Precautions).
Use for glycemic control is not recommended in patients with an eGFR less than 30 mL/min/1.73m² (see Precautions).
Assess volume status. In patients with volume depletion, correct this condition before initiating JARDIANCE (see Precautions).
Recommended Dosage: Table 22 presents the recommended dosage of JARDIANCE in adult and pediatric patients aged 10 years and older. (See Table 22.)

Click on icon to see table/diagram/image

Patients with hepatic impairment: No dose adjustment is recommended for patients with hepatic impairment.
Elderly Patients: No dosage adjustment is recommended based on age. In patients 75 years and older, an increased risk for volume depletion should be taken into account (see Precautions and Adverse Reactions).
Combination therapy: When JARDIANCE is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see Interactions and Adverse Reactions).
Missed dose: If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
Paediatric population: The safety and effectiveness of JARDIANCE have not been established in pediatric patients less than 10 years of age as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.
The safety and effectiveness of JARDIANCE have not been established in pediatric patients to reduce the risk of: cardiovascular death and hospitalization for heart failure in patients with heart failure; sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in patients with chronic kidney disease at risk of progression; cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
In the trial of pediatric patients aged 10 to 17 years with type 2 diabetes mellitus, patients with an eGFR less than 60 ml/min/1.73 m² were not enrolled (see general information as previously mentioned).